ClinicalTrials.gg
RecruitingNCT05829733Updated Dec 12, 2025

6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis

An interventional study of SYNOLIS VA 80/160 in Osteoarthritis, Hip, sponsored by Aptissen SA. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Aptissen SA · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Osteoarthritis, Hip with a site in France — 10 open to participants now, 16 under way, none of them phase 3. Osteoarthritis, Hip · France.

Planned enrollment
15th of 20
70 · median 130
Started
2024
with 6 others
No phase
11 of 38
3 open now
Primary completion
2027-04
later than 9 of 15 live
Registered
31st of 38
by date
Lead sponsor
1 of 38
Aptissen SA

Among the 38 studies in Osteoarthritis, Hip with a site in France, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, reaches primary completion later than 9 of the 15 other live ones, and was the 31st registered.

Osteoarthritis, Hip

642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.

Browse Osteoarthritis, Hip studies →

Open to participants now

10 of the 38 studies in Osteoarthritis, Hip with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Osteoarthritis, Hip with a site in France, or all of them as a file.
02

Study summary

Multicenter, independent study of Synolis VA 80/160 over a period of 6 months

03

Conditions studied

  • Osteoarthritis, Hip

Keywords

  • Osteoarthritis
  • Hip osteoarthritis
  • Hyaluronic acid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years of age,
  • Patient with osteoarthritis of the hip. The diagnosis is based on the following criteria:
  • Treated hip pain: Oxford score ≥ 21/60,
  • Kellgren-Lawrence positive X-ray stage: II - III (inclusion radiograph dated no more than 6 months before the inclusion visit),
  • Symptoms related to osteoarthritis of the hip for at least 2 months,
  • Failure of treatments (i.e., inadequate or ineffective response to analgesics and/or NSAIDs or intolerance to NSAIDs or low-grade opioids (leaving an OXFORD score ≥ 21/60),
  • form signed by the patient,
  • The patient has never had a visco supplement injection or injection in the hip to be treated (or more than 6 months old).

Exclusion criteria

Exclusion Criteria:

  • Pregnancy,
  • Participation in another clinical trial,
  • Skin lesion near the injection site,
  • Recent or old infection of the affected joint,
  • Patient with a programmed arthroplasty,
  • Patient with a pathology that makes decision-making impossible,
  • The patient must not have undergone non-prosthetic hip-conserving surgery such as osteotomy or arthroscopy less than 12 months old.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    SYNOLIS VA 80/160

    Single guided intra-articular injection of SYNOLIS VA 80/160

    Device: SYNOLIS VA 80/160

Interventions

  • DeviceSYNOLIS VA 80/160

    SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)

06

What researchers measure

Primary outcomes

  1. Evolution of the Oxford Hip Score (OXFORD 12)

    Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.

    Time frame: 6 months (M6)

Secondary outcomes

  1. Evolution of the Oxford Hip Score (OXFORD 12)

    Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.

    Time frame: Month 3, Month 3 to Month 6

  2. Self-assessment symptoms evolution

    7-point Likert scale (-3 to +3)

    Time frame: Month 3, Month 3 to Month 6

  3. MCID Oxford Hip Score (OXFORD 12)

    Minimum clinically important difference on the Oxford Hip Score (OXFORD 12)

    Time frame: Month 3, Month 3 to Month 6

  4. Hip prosthesis placement after the injection

    Number of Participants with Hip prosthesis placement

    Time frame: Month 6

Other outcomes

  1. Safety and tolerability of SYNOLIS VA 80/160

    Serious adverse event occurrence

    Time frame: Month 6

07

Study locations

3 of 3 sites recruiting
  • Service de Rhumatologie, Hôpital Nord Franche-Comté
    Belfort, France
    Recruiting
    • Thierry Conrozier, Dr · Contact
  • Service de chirurgie orthopédique et traumatologie Centre Hospitalier de Dunkerque CHD
    Dunkirk, France
    Recruiting
    • Nicolas Jan, Dr · Contact
  • Service d'Orthopédie II (Membre Inférieur, Chirurgie du Sport et Chirurgie Septique) Hôpital Salengro, CHRU de Lille
    Lille, France
    Recruiting
    • Henri Migaud, Pr · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Apr 2027, 35 months after the start.

Of 227 interventional studies with no phase under Osteoarthritis, Hip, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 26, 2023
StartActual
May 27, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05829733
Lead sponsor
Aptissen SA
Responsible party
Sponsor
First posted
Apr 26, 2023
Start date
May 27, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Dec 12, 2025

Study contacts

Eduard Vidovic, MD
Contact
clinic@aptissen.com
+41225522104

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion